Accessibility Menu
Oragenics logo

Oragenics(NYSEMKT) OGEN

Market Cap$2.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-100%
5 Year-100%
1 Year-51%
1 Month+2%
$0.51
-2.75%
-0.01Today
Oragenics last closing stock price
MetricPriceDate
Last closeUSD 0.512026-08-31
Oragenics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.87%USD 0.522026-08-24
1 month+1.96%USD 0.502026-07-31
3 month-16.43%USD 0.612026-06-02
Year to date-34.91%USD 0.782025-12-31
1 year-50.5%USD 1.032025-08-29
3 year-99.51%USD 104.102023-09-01
5 year-99.96%USD 1,286.102021-09-01
Since inception-100%USD 1,080,108.012003-07-09

Oragenics Financials at a Glance

Market Cap

$2.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.08M

EPS (TTM)

-$3.58

P/E Ratio

-0.15

Dividend

$0.00

Beta (Volatility)

0.98 (Low)

Price

$0.51

Volume

101,210

Open

$0.52

Previous Close

$0.51

Daily Range

$0.49 - $0.53

52-Week Range

$0.48 - $1.45

Estimated Earnings Date

Nov 16, 2026

OGEN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oragenics

Oragenics develops medicines for brain injuries and infectious diseases. Its main product aims to help people recover from concussions. The company focuses on treatments that could fill gaps where no approved drugs exist.

Lab Bench to Bedside: Oragenics’ Main Offerings

  • ONP-002 (Neurosteroid): Intranasal treatment for mild traumatic brain injury, targeting people with concussions. (0% of revenue; pre-commercial)
  • NT-CoV2-1: Nasal vaccine candidate for COVID-19, aimed at respiratory disease prevention. (0% of revenue; development paused)
  • Terra CoV-2: Injectable COVID-19 vaccine candidate for broader population use. (0% of revenue; development paused)
  • LPT3-04: Experimental weight loss drug, targeting obesity. (0% of revenue; development paused)
  • SMaRT Replacement Therapy: Topical treatment to prevent dental cavities, for dental health. (0% of revenue; development paused)

Plot Twists and Partnerships: Growth & Expansion Moves

  • Signed a license agreement with Noachis Terra in 2020 for coronavirus spike protein technology.
  • Formed collaborations with Precigen and ILH Holdings for antibiotic development (year not specified).
  • Shifted strategic focus in 2025 to prioritize ONP-002, pausing other programs.
  • Raised $15 million in July 2025 through preferred stock and warrants to fund clinical trials.
  • Expanded clinical operations to Australia in 2026 for Phase 2a ONP-002 trial.

Why Oragenics Stands Out (Without Standing Too Tall)

Oragenics uses a patented nasal delivery device for direct brain treatment. The company holds intellectual property rights in major markets, including the US and Europe. Its focus on concussion therapy addresses a medical need with no approved drug treatments.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Operating loss was $9.4 million in 2025, improving 11.3% from 2024.
  • Research and development spending fell 41.8% to $2.4 million in 2025.
  • Cash and equivalents totaled $8.4 million at December 31, 2025.

Bottom Line

Oragenics has narrowed its focus to concussion treatment using a novel nasal drug delivery. The company remains pre-revenue and relies on external funding for continued operations.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

Janet Huffman

Website

www.oragenics.com

Headquarters

Lakewood Ranch, FL 34202, US

OGEN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-144.23%

Return on Capital

-110.03%

Return on Assets

-183.59%

Earnings Yield

-6.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.51M

Volume

101.21K

Avg. Volume

37.10K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$10.47M

EBITDA

-$7.15M

Operating Cash Flow

-$10.21M

Capital Expenditure

$1.00

Free Cash Flow

-$10.21M

Cash & ST Invst.

$3.86M

Total Debt

$0.00

Oragenics Performance Analysis

Oragenics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Oragenics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Oragenics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -213.35-14.8%
20232023-12-31USD -275.4529.1%
20242024-12-31USD -47.88-82.6%
20252025-12-31USD -4.56-90.5%
Oragenics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3036.8%
Q42025-12-3172.4%
Q12026-03-315.6%
Q22026-06-30-11.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$788.40K

N/A

Employees

3

N/A

Net Income

-$2.53M

-11.3%

EBITDA

-$2.58M

-51.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.86M

+95.8%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.84%

N/A

Return on Invested Capital

-2.85%

N/A

Free Cash Flow

-$2.19M

-66.4%

Operating Cash Flow

-$2.19M

-66.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TTNPTitan Pharmaceuticals, Inc.
$2.34-11.36%
QLGNQualigen Therapeutics, Inc.
$3.21+5.59%
SNGXSoligenix, Inc.
$0.38+0.85%
ENSCEnsysce Biosciences, Inc.
$0.39-1.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About OGEN

What is the current price of Oragenics?

Oragenics is trading at $0.51 per share.

What is the 52-week range for Oragenics?

Over the past 52 weeks, Oragenics has traded between $0.48 and $1.45.

How much debt does Oragenics have?

As of the most recent reporting period, Oragenics reported total debt of $0.00.

How much cash does Oragenics have on hand?

Oragenics reported $3.86M in cash and cash equivalents in its most recent financial results.

What is Oragenics’s dividend yield?

Oragenics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services